← All trials
NCT05575076
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 7, 2022
- Primary completion
- Jul 15, 2026
- Completion date
- Jul 15, 2026
- First posted
- Oct 12, 2022
- Last posted
- Nov 23, 2022
- Enrollment
- 1600
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cassava SciencesLead sponsor
- Cassava SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.